Page last updated: 2024-12-05

terpin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Terpin is a naturally occurring monoterpene alcohol found in essential oils from various plants, such as pine, fir, and orange. It is commonly produced synthetically from turpentine. Terpin is known for its expectorant properties and is used in cough syrups and other medications to help loosen mucus in the respiratory tract. It is also used as a fragrance ingredient in cosmetics and perfumes. Research into terpin's effects and potential therapeutic uses is ongoing, with studies exploring its antioxidant, anti-inflammatory, and antimicrobial properties. Its importance lies in its potential applications in treating respiratory ailments and other medical conditions.'

terpene : A hydrocarbon of biological origin having carbon skeleton formally derived from isoprene [CH2=C(CH3)CH=CH2]. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6651
CHEMBL ID1651998
CHEMBL ID1414114
CHEMBL ID1513871
CHEBI ID179539
CHEBI ID134806
SCHEMBL ID19192
SCHEMBL ID9536260
SCHEMBL ID5377815
MeSH IDM0047570

Synonyms (91)

Synonym
STL356461
CHEBI:179539
4-(2-hydroxypropan-2-yl)-1-methylcyclohexan-1-ol
trans-p-menthane-1,8-diol
cyclohexanemethanol, 4-hydroxy-.alpha.,.alpha.,4-trimethyl-
NCI60_003817
4-(1-hydroxy-1-methylethyl)-1-methylcyclohexanol
80-53-5
1,8-terpin
nsc-403856
terpin
p-menthane-1,8-diol
cyclohexanemethanol,.alpha.,4-trimethyl-
nsc403856
NCGC00166136-01
NCGC00159414-03
NCGC00159414-02
CHEBI:134806
cis-p-menthane-1,8-diol
T2344
NCGC00159414-05
NCGC00159414-06
NCGC00159414-04
cis-p-menthan-1,8-diol
CHEMBL1651998
cis-1,8-p-menthanediol
nsc 403856
ec 201-288-2
4-hydroxy-alpha,alpha,4-trimethylcyclohexanemethanol
terpin (van)
einecs 201-288-2
terpin [ban]
cyclohexanemethanol, 4-hydroxy-alpha,alpha,4-trimethyl-
cas-80-53-5
tox21_111646
dtxsid7023643 ,
dtxcid903643
AKOS024348939
pharmakon1600-01506188
nsc760418
565-48-0
mpf495b08r ,
einecs 209-279-5
unii-mpf495b08r
cis-4-hydroxy-alpha,alpha,4-trimethylcyclohexanemethanol
4-(2-hydroxypropan-2-yl)-1-methylcyclohexanol
565-50-4
trans-terpin
terpene
cyclohexanemethanol, 4-hydroxy-.alpha.,.alpha.,4-trimethyl-, cis-
terpin [who-dd]
terpin [mi]
cyclohexanemethanol, 4-hydroxy-.alpha.,.alpha.,4-trimethyl-, trans-
(1r,4r)-4-(2-hydroxypropan-2-yl)-1-methylcyclohexan-1-ol
terpin monohydrate impurity d [ep impurity]
AKOS022099020
4-p-menthan-1,8-diol
cyclohexanemethanol, 4-hydroxy-alpha,alpha,4-trimethyl-, trans-
trans-1,8-p-menthanediol
4hw1s44t5g ,
trans-p-menthan-1,8-diol
unii-4hw1s44t5g
terpin, trans-
trans-1,8-terpin
terpin trans-form [mi]
SCHEMBL19192
SCHEMBL9536260
NCGC00159414-01
SCHEMBL5377815
dipenteneglycol
p-mentha-1,8-diol
4-(1-hydroxy-1-methylethyl)-1-methylcyclohexanol #
W-107311
BBL034665
CHEMBL1414114
CHEMBL1513871
4-(2-hydroxy-2-propanyl)-1-methylcyclohexanol
AB01563167_01
trans-terpin, analytical standard, for gc
terpinhydrat
AKOS037514988
CS-0032749
HY-N4324
cis-4-hydroxy-|a,|a,4-trimethylcyclohexanemethanol
Q27284154
Q27259605
trans_terpin
AS-83272
DTXSID501031803
DTXSID401031800
PD132153

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
p-menthane monoterpenoid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency17.78280.003245.467312,589.2998AID2517
DNA polymerase kappa isoform 1Homo sapiens (human)Potency26.67950.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID555348Effect on growth in Staphylococcus aureus MN8 at 37.50 mM after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID555381Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 7.50 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID555349Effect on growth in Staphylococcus aureus MN8 at 7.50 mM after 24 hrs (Rvb = 100%)2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
AID555380Induction of toxin TSST-1 production in Staphylococcus aureus MN8 at 37.50 mM after 24 hrs relative to control2009Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5
Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (7.69)18.7374
1990's2 (5.13)18.2507
2000's14 (35.90)29.6817
2010's17 (43.59)24.3611
2020's3 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.54 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index5.24 (4.65)
Search Engine Demand Index103.70 (26.88)
Search Engine Supply Index2.07 (0.95)

This Compound (62.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.44%)5.53%
Reviews2 (4.88%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other38 (92.68%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomised, Double-blinded, Pilot Study Investigating the Safety and Efficacy of Topical P-menthane-3,8-diol Oil Extract in the Treatment of Childhood Impetigo. [NCT01611909]Phase 2/Phase 330 participants (Anticipated)Interventional2012-07-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]